Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE AAA Research Reports
LONDON, January 16, 2014 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
On Wednesday, January 15, 2014, the US equity market ended on a higher note as the S&P 500 closed the day at 1,848.38, up 0.52%; the Dow Jones Industrial Average ended at 16,481.94, up 0.66%; and the NASDAQ Composite finished at 4,214.88, up 0.76%. The S&P 500 Health Care Sector Index edged 0.14% lower to end the day at 659.40. The S&P 500 Pharmaceuticals Sub Industry Index ended the day at 504.17, down 0.29%; while the same has gained 5.50% in the last one month and 10.63% in the previous three months, outperforming the S&P 500, which has advanced 4.12% and 8.85% during the respective periods. The major movers in the industry included Zoetis Inc. (NYSE: ZTS), AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR), Actavis PLC (NYSE: ACT), and Salix Pharmaceuticals Ltd (NASDAQ: SLXP). All these companies are tracked by AAAResearchReports.com. Free technical research on ZTS, AVNR, ACT, and SLXP can be downloaded upon signing up at:
On Wednesday's, Zoetis Inc.'s stock ended the day at $31.81, which is 0.13% lower than the previous day's closing price of $31.85. The company's shares vacillated between $31.68 and $31.96 during the trading session. A total of 2.92 million shares were traded, which is below the daily average volume of 3.32 million. The company's shares have fallen by 2.24% in the previous three trading sessions and 0.81% in the last three months, underperforming the S&P 500, which has gained 0.33% and 8.85% during the respective periods. However, Zoetis Inc.'s stock is trading above its 50-day and 200-day moving averages of $31.77 and $31.65, respectively. Sign up and read the complimentary report on ZTS at:
Shares in AVANIR Pharmaceuticals Inc. rallied on Wednesday, as the broader market edged higher. The company's stock finished the day at $3.81, up 5.83% from the previous day's closing price of $3.60. A total of 2.62 million shares were traded, which is above the daily average volume of 2.49 million. The company's shares have surged 17.59% in the previous three trading sessions and 34.39% in the last one month, outperforming the S&P 500, which has advanced 0.33% and 4.12% during the respective periods. Furthermore, AVANIR Pharmaceuticals Inc.'s stock is trading above its 50-day moving average of $3.79. The free report on AVNR can be downloaded by signing up now at:
On Wednesday, Actavis PLC's stock declined to close the day at $181.80, down 2.26% from the previous day's closing price of $186.00. The company's shares fluctuated between $181.28 and $186.34 during the trading session. A total of 1.89 million shares were traded, which is above the daily average volume of 1.28 million. Despite Wednesday's decline, the company's shares have surged 13.75% in the last one month and 29.36% in the previous three months, outperforming the S&P 500, which has advanced 4.12% and 8.85% during respective periods. Moreover, Actavis PLC's stock is trading above its 50-day and 200-day moving averages of $164.70 and $136.33, respectively. A free report on ACT can be accessed by registering at:
Shares in Salix Pharmaceuticals Ltd traded between $94.92 and $97.85 before ending Wednesday's session 1.33% lower at $95.30. A total of 0.87 million shares were traded, which is below the daily average volume of 0.89 million. Despite Wednesday's pullback, the company's shares have surged 13.38% in the last one month and 39.53% in the previous three months, outperforming the S&P 500, which has advanced 4.12% and 8.85% during respective periods. Additionally, Salix Pharmaceuticals Ltd's stock is trading above its 50-day and 200-day moving averages of $85.85 and $69.76, respectively. Register with AAA Research Reports and download research on SLXP for free at:
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.